Clinical Trial Update: Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 neoadjuvant trial for oral cancer evaluating a Benmelstobart and anlotinib combination with chemotherapy. The study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Benmelstobart

Snippet

Sponsor: Jiangsu Cancer Institute & Hospital | Conditions: Mouth Neoplasms, Neoadjuvant Therapy | Phase 2 | Status: NOT_YET_RECRUITING